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Objective: To determine the association of epilepsy with incident dementia we 
conducted a nation-wide retrospective data-linkage, cohort study, to examine 
whether the association varies according to dementia subtypes and investigate 
whether risk factors modify the association.   
Methods: We used linked health data from hospitalisation, mortality records and 
primary care consultations to follow-up 563,151 Welsh residents from their 60th 
birthday to estimate dementia rate and associated risk factors. Dementia, 
epilepsy and covariates (medication, smoking, comorbidities) were classified 
using previously validated code lists. We studied rate of dementia and dementia 
subtypes in people with epilepsy (PWE) and without using (stratified) Kaplan-
Meier plots and flexible parametric survival models. 
Results: PWE had a 2.5 (95% CI 2.3 to 2.6) times higher hazard of incident 
dementia, a 1.6 (95% CI 1.4 to 1.8) times higher hazard of incident Alzheimers 
disease (AD), and a 3.1 (95% CI 2.8 to 3.4) times higher hazard of incident 
Vascular dementia (VaD). The increased incidence in PWE was modified by a 
history of stroke. PWE who were first diagnosed at age 25 years or younger had 
a similar dementia rate compared to those diagnosed later in life. PWE who had 
ever been prescribed sodium valproate compared those who had not, were at 
higher risk of dementia (HR: 1.6; 99% CI: 1.4 to 1.9) and VaD (HR: 1.7; 99% CI: 
1.4 to 2.1), but not AD (HR: 1.2; 99% CI: 0.9 to 1.5). 
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Conclusion: People with epilepsy, compared to those without epilepsy, have an 
increased dementia risk. 
 
INTRODUCTION 
With increasing longevity comes the risk of developing dementia after age sixty 
years. By 2035, an estimated 10.5 million people will be living with dementia in 
Europe and 22.7 million in Asia [1]. Dementia may be classified according to 
presumed aetiology with Alzheimer’s Disease (AD) and Vascular Dementia 
(VaD) being the most common subtypes. Given lack of successful disease-
modifying treatments for dementia, identification of potentially modifiable risk 
factors is paramount. 
 
The risk of developing dementia increases with increasing age and is associated 
with genetic variants, several environmental risk factors and other diseases, 
including epilepsy [2]. However, the relationship between dementia and epilepsy 
is likely to be complex, because epilepsy is a risk factor for dementia while 
having dementia is a risk factor for developing epilepsy.  
 
Although there are numerous studies examining the association between 
established or recently diagnosed dementia and subsequent development of 
epilepsy, few have investigated risk of dementia in people with epilepsy (PWE) 
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[3–6]. There is concern that drugs used to treat epilepsy may increase the 
incidence of dementia, and not the epilepsy per se [7].  
 
The aims of the current study were to compare the hazard of dementia overall, 
of AD and VaD between PWE: 
1. and people without epilepsy; adjusting for potential socio-demographic and 
clinical confounding/effect modifying factors. 
2. with an epilepsy diagnosis at age 25 years or younger versus PWE diagnosed 
older 
3. exposed to specific AEDs and PWE not exposed   
 
METHODS 
We report this study in accordance with the Standards of Reporting of 
Neurological Disorders (STROND). 
This is a retrospective cohort study using the Secure Anonymised Information 
Linkage (SAIL) Databank [8]. SAIL provides linked health care-related information 
for 4-5 million (alive and deceased) residents of Wales. It contains coded 
information from general practice (GP) consultations (including prescriptions) 
linked to hospital admissions and death registrations data sets, for approximately 
80% of the Welsh population. Primary care data in SAIL are coded using the Read 
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version 2 system, with hospital admissions and death registrations data coded 
using the International Classification of Diseases 10 (ICD-10) system. SAIL has 
been used for a number of epilepsy studies [9–11]. It holds information on a 
dementia e-cohort (SAILDeC) recently created by two of the authors (TW and CS) 
to allow dementia researchers easy access to linked health data in a described 
cohort [12] and this dementia e-cohort was used in the current study.  
 
Study population, inclusion and exclusion criteria 
563,151 residents of Wales, UK, were followed up passively from their 60th 
birthday to dementia diagnosis, death or the end of follow-up on June 2018. 
Median year at the start of follow-up (60th birthday) was 2006 (IQR: 2001 to 
2011). People were included if, at the time of their 60th birthday, they had been 
registered with a Welsh GP practice that had signed up to SAIL. Residents were 
excluded if they have had a dementia related health record prior to their 60th 
birthday.  
To study the effect of age at epilepsy diagnosis and exposure to AEDs on 
dementia risk we excluded people without epilepsy. Finally, to study the effect 
of exposure to AEDs on the risk of dementia, we only included PWE with at least 
one code in the primary care data for a prescription for an AED. 
Dementia was classified using dementia-related diagnostic codes in the routinely 
collected, coded, electronic health records (codes used to identify and classify 
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dementia subtypes are available from the Edinburgh University Data Share point 
https://datashare.is.ed.ac.uk/handle/10283/3574). Application of combinations of 
those codes in a recent UK validation study has shown positive predictive values 
(PPVs) of 83%, 71% and 44% for dementia, AD and VaD respectively[13].  
 
Where records/codes allowed, dementia was further subclassified into AD and 
VaD; because of low numbers, dementia with Lewy bodies, mixed dementia and 
frontotemporal dementia were not analysed as separate subclasses. Because the 
diagnosis of AD and VaD is often preceded by an unspecific dementia diagnosis 
we used the date of first dementia related record as the time of diagnosis for all 
analysis. People diagnosed with AD are at very low risk to be subsequently 
diagnosed with VaD, so when we compared the risk of AD in those with and without 
epilepsy, we used the actual diagnosis of AD as outcome and excluded people 
from the study population who had dementia without subtype information or with a 
diagnosis of VaD. Similarly, when we compared the risk of VaD we excluded 
people without dementia sub-type information or with a diagnosis of AD. 
 
Exposures 
People with at least one diagnostic ICD-10 and Read codes for epilepsy were 
classified as PWE, with the date of first record taken as the date of diagnosis 
(codes used to identify epilepsy diagnoses are available from the Edinburgh 
University Data Share point https://datashare.is.ed.ac.uk/handle/10283/3574). 
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These validated codes have a sensitivity of 86% (95%CI 8-91%) and a specificity 
of 97% (95%CI 92–99%) [9].  PWE were defined as “exposed” if they had any 
epilepsy-related diagnosis at any time before or during follow-up. Because 
follow-up ended with the first dementia-related diagnosis, people who had an 
epilepsy-related diagnosis after their first dementia diagnosis were considered 
as non-exposed (epilepsy-free) in our analyses.  To address the issue of 
potential reverse causality, we took into consideration the uncertainty about the 
length of pre-clinical phase in dementia and that epilepsy may be an early sign 
of dementia.  We carried out an additional, sensitivity, analysis excluding 120 
epilepsy cases that were diagnosed less than 1 year prior to incident coded 
dementia diagnosis.    
 
Linked EHR were used to classify exposure to cardio-metabolic risk factors 
(smoking status, hypertension and alcohol misuse), stroke, diabetes, head 
injuries and bipolar disorder (see 
https://datashare.is.ed.ac.uk/handle/10283/3268 for a list of codes). Smoking 
history was classified using Read codes related to tobacco exposure; individuals 
where no information on smoking status was available were classified as non-
smokers. We applied a similar approach for the other potential modifiers; if we 
found indications for them (e.g. code for stroke) then they were classified positive 
but if we don’t find them, they were classified as negative. In addition, 
administrative data were used to classify sex, age and socio-economic status 
(2012 Welsh Index of multiple deprivation, WIMD). WIMD was classified as 
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deprivation quintile at the 60th birthday (start of follow up). Finally, records from 
primary care consultations were used to classify exposure to AEDs (see table 1 
for a code list which was obtained from NHS digital 
(https://isd.digital.nhs.uk/trud3/user/guest/group/0/pack/9)). For statistical 
reasons, we only analysed the effect of AEDs with more than 100 exposed PWE 
in the study population. People with at least two records of an AED spaced at 
least 30 days from each other were defined as exposed, independent of dose or 
the period of exposure. Exposure to any of the AED was compared to non-
exposure to that specific drug (exposure to at least one of the other AEDs). 
 
Statistics 
The risk of incident dementia diagnosis was analysed using parametric survival 
analysis in R (packages survreg and flexsurv). Exposure to epilepsy or any of 
the covariates, including exposure to AEDs, was analysed as time independent, 
e.g., exposed people were classified ‘exposed’ independent of year or age at 
exposure. We tested different parametrizations (Weibull, exponential, Gaussian, 
logistic, lognormal and loglogistic) and selected the best fitting model (based on 
Akaike information criterion). While the survival model based on the Weibull 
distribution had the best fit, visual comparison of the predicted risk with a Kaplan-
Meier plot showed decreasing fit with increasing age. Therefore, we used a 
Royston-Parmar flexible parametric survival model for analysis [14]. All 
statistical models were adjusting for the effect of sex, while starting follow up for 
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each person at their 60th birthday controlled for the effect of age. Since some of 
the variables were highly correlated, and some may be along the causal 
pathway, to study whether the effect of epilepsy on dementia incidence was 
associated with exposure to individual cardio-metabolic risk factors (smoking 
status, hypertension and alcohol misuse), stroke, diabetes, head injuries, bipolar 
disorder or deprivation on their own, we compared estimated HRs for the effect 
of epilepsy in survival models that control for exposure to any of the variables 
singly with estimated HRs from models without control. 
 
The flexible parametric survival model was also used to study the effect of young 
onset epilepsy and exposure to an AED compared to any other AED on the risk 
of dementia in PWE.  Because initial results from the modelling were suggestive 
of an association between sodium valproate exposure and stroke and because 
we expected an association between sodium valproate exposure and bipolar 
disorder in people with epilepsy, we additionally compared two models of the 
effect of sodium valproate exposure on the hazard of dementia, AD and VaD 
with and without controlling for having a diagnosis of stroke and of bipolar 
disorder.  
We provide estimates along with either 95% confidence intervals (95%CIs) or to 
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Data availability 
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Fifty percent of the study population were male. Information on deprivation was 
available for 540250 (96%) with 97,853 from the most affluent areas (WIMD 1) 
and 123,456 from areas with worst deprivation (WIMD 5); 373,125 had 
indications of ever-smoking, 36,743 of a stroke and 28,153 of a head injury 
before or during follow-up. Total follow up time was 5,944,283 person-years with 
median follow-up time of 10 years. 97,622 people died during follow up with 
median age of death at 69 years. 
Sixteen thousand and seven hundred (16,700) of the cohort had dementia, of 
which 6,916 were classified as having AD and 5005 having VaD. 1060 had 
codes for both AD and VaD, and 5839 had unspecified dementia and could not 
be subtyped.  Median age at diagnosis of dementia in people without epilepsy 
was 73 years, and 74 years each for AD and VaD (Figure 1).  
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There were 19,150 (3.4%) PWE with a bimodal distribution of age at diagnosis 
(Figure 2). 3274 had an epilepsy diagnosis on or before their 25th birthday, and 
12,331 at age 26 years or older but before their 60th birthday. Fifty percent of 
PWE died within 19 years of their 60th birthday compared to those without 
epilepsy of whom 50 percent had died within 24 years of their 60th birthday. 
12,797 PWE (67%) had exposure to at least one AED, the majority to sodium 
valproate, carbamazepine and gabapentin (Table 1). A substantial proportion of 
the cohort had ever had an AED prescription although they did not have a 
recorded epilepsy diagnosis; most of this was prescription for gabapentin and 
pregabalin that are often prescribed for other indications such as chronic pain. 
Others with an AED prescription, such as phenytoin and levetiracetam that are 
fairly specific drugs for epilepsy, but without concurrent epilepsy diagnosis 
codes might have been diagnosed prior to the start of EHR data collection and 
would therefore be misclassified as not having epilepsy. If this were the case, 
we would not expect substantial bias due to the high sensitivity and specificity 
of epilepsy diagnostic codes in SAIL. 
Compared to people without epilepsy, PWE had a 2.5 (95% CI 2.3 to 2.6) times 
higher hazard of incident dementia, a 1.6 (95% CI 1.4 to 1.8) times higher 
incidence of AD, and a 3.1 (95% CI 2.8 to 3.4) times higher hazard of incident 
VaD (Table 2 and Figure 3). Within 21, 26 and 25 years of follow-up from their 
60th birthday, 20% of PWE are predicted to have had a diagnosis of any 
dementia, AD and VaD. Within 25 and 31 years the hazard increases to 40% for 
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any dementia and VaD, respectively; for AD, within 31 years the hazard was 
31%. When 120 PWE who were diagnosed with epilepsy less than a year prior 
to dementia diagnosis were excluded from analysis, the HR for dementia, AD 
and VaD were slightly reduced to 2.3 (95% CI 2.1 to 2.4), 1.5 (95% CI 1.3 to 
1.7) and 2.7 (95% CI 2.5 to 3.0).  Table 2 shows that the increased HR of incident 
dementia in PWE (HR: 2.5) did not change substantially when we controlled 
individually for the effect of smoking, hypertension, social deprivation, alcohol, 
diabetes, head injury or depression. However, controlling for stroke did reduce 
the estimated HR for dementia from 2.5 to 2.0 (95% CI 1.9 to 2.1) and for VaD 
from 3.1 to 2.0 (95% CI 1.8 to 2.3). 
 
The hazard for dementia, AD or VaD was not different in people diagnosed with 
epilepsy at age 25 years or younger versus those diagnosed with epilepsy at an 
older age (Figure 3). 
 
Amongst AEDs investigated, only exposure to sodium valproate and lamotrigine 
showed statistically significant increased hazard ratios for dementia or AD or 
VaD (Table 3). For PWE having ever been prescribed sodium valproate 
compared to any other AED was associated with higher hazards for dementia, 
and VaD but not for AD. Within 17 years of follow-up from their 60th birthday, 
20% of PWE ever-exposed to sodium valproate are predicted to have had a 
diagnosis of any dementia; within 23 years the hazard increases to 40% (Figure 
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4). Exposure to lamotrigine compared to any other AED was associated with a 
higher hazard ratio for AD only, but not for dementia or VaD (Table 3). 
 
The addition of an indicator for stroke or bipolar disorder to the flexible 
parametric survival model predicting the effect of VPA exposure on the hazard 
of dementia did not substantially change the estimated HR for dementia, AD or 
VaD (Table 3). 
 
DISCUSSION 
The main findings of this study are: (1) PWE had a 2.5 (95%CI 2.3to 2.6) times 
higher hazard of incident dementia, a 1.6 (95% CI 1.4 to 1.8) times higher hazard 
of incident AD and a 3.1 (95%CI 2.8 to 3.4) times higher hazard of incident VaD 
compared to people without epilepsy - some of this increased risk in incident 
dementia and VaD can seemingly be explained partly, but not wholly, by PWE 
having a higher risk of stroke which in turn was associated with an increased risk 
of VaD; (2) the incidence of dementia in PWE was not associated with age at 
diagnosis of epilepsy; (3) PWE ever exposed to sodium valproate compared to any 
other AED had a higher incidence of dementia. However, ultimately, findings from 
analyses such as these from routine administrative health data that were not 
collected originally for research, are hypothesis generating and help inform future 
work. The current study cannot be used to establish a cause–effect relationship 
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due to the intrinsic study design and source of data. Further, prospective studies 
are required to establish temporality.  
 
Cognitive impairment, mood and behavioural disturbance, all of which are 
features of dementia, have long been reported in PWE. There are data that 
suggest that such disturbances are worse with increased seizure burden which 
may be due to long duration of epilepsy, higher seizure frequency, higher 
seizure severity. We were unable to determine details of epilepsy characteristics 
including aetiology, severity and seizure frequency, so it is possible that there 
may have been some patients with frequent or even subclinical seizures or an 
epileptic encephalopathy whose condition mimicked dementia [15] and our 
results need to be considered in that light.   If seizure burden does at least 
partially contribute to cognitive impairment, improvement in epilepsy 
management may decrease dementia risk which is supported by recent work 
showing subclinical epileptic discharges in the hippocampus in people with 
dementia and improvement in cognition when treated with an AED lamotrigine. 
The potential adverse cognitive effects of AEDs and their associated usage with 
dementia has been described [16], and it is possible that our finding is partly 
attributable to exposure to AEDs. On the other hand, cognitive impairment has 
also been observed in newly diagnosed patients with epilepsy before the 
inception of AEDs [17] and has been found in first degree relatives of patients 
with idiopathic generalised epilepsy. This would suggest the presence of an 
endophenotype for some epilepsy syndromes and points to an underlying 
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process independent of AEDs that leads to the parallel development of seizures 
and cognitive impairment [18]. 
We investigated potential socio-demographic and clinical confounding/effect 
modifying factors but aside from a diagnosis of stroke, increased risk of incident 
dementia in PWE persisted. The fact that risk of VaD but not AD was attenuated 
with a diagnosis of stroke, may be related to challenges with classification of 
dementia in a clinical setting. Patients with a history of stroke might be more 
likely to be diagnosed as having VaD in routine clinical practice, even if some 
concurrent AD pathology is present in reality. 
 
We were surprised to observe there was no difference of risk for incident 
dementia according to age of initial epilepsy diagnosis because we hypothesised 
that longer duration of epilepsy may increase risk. However, we were unable to 
adjust for other epilepsy characteristics such as seizure frequency and aetiology 
which may also affect risk and could be correlated with epilepsy duration. In 
addition, while we did observe the expected bimodal distribution of age at 
epilepsy diagnosis (Figure 2), an unknown, presumed small proportion of PWE 
will have been misclassified as late-onset epilepsy because data going back 
long enough to show they were really diagnosed in early life were not available. 
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The reasons for taking or not taking antiepileptic treatment and the choice of 
treatment may be related to variables that influence the risk of dementia such as 
age, gender and education level. We had no data on indication for choice, 
duration of length of exposure, nor dosage of any of the AEDs examined in the 
current study so indication bias cannot be rule out.  It would not be unreasonable 
to consider the findings of increased risk of dementia associated with anti-
epileptic treatment as questionable. For many years sodium valproate’s broad 
spectrum of anti-epileptic effects made it a popular first line AED [19]. It is only 
in the last decade that serious reservations about its use in certain populations 
have been expressed. It was, however, used as a drug of choice for the elderly 
for many years [19]. One often unnoticed side effect is the development of an 
encephalopathy which in the older age group might be mistaken for dementia 
[20, 21]. Given the sodium valproate was often used in post-stroke seizures it is 
conceivable some patients in the current study might have been misdiagnosed 
as VaD when in fact they had a reversible drug side effect. However, there is 
some available information that provide some potential biological plausibility to 
our cautious finding of valproate exposure and increased dementia risk.  Sodium 
valproate has a number of unwanted effects that may predispose to 
cerebrovascular disease in later life. Changes in lipid profiles, insulin resistance 
and the development of the metabolic syndrome have been reported in children 
and adults exposed to the drug [22]. Thus, further studies are needed to examine 
our observed association.   
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Strengths and Weaknesses 
The strengths of this study lie in the unique large scale, population-based, 
longitudinal linked data that covers 80% of the Welsh population in SAIL which 
allowed us to apply a cohort design and to estimate absolute hazards. However, 
follow-up data from GP practices in SAIL started from 2000 to present; from 
1991 to present for hospital admission data and from 1995 to present for death 
registrations. The extent to which GP data are retrospectively coded from paper 
records of early years of life into electronic health record varies from GP practice 
to GP practice. Since our study population is restricted to those followed up from 
their 60th birthday, and given the above, it is uncertain what percentage of study 
subjects were covered throughout their life resulting in some possible exposure 
bias.  Misclassification bias may exist from the case definition for epilepsy 
despite the high sensitivity and specificity of diagnoses in SAIL.  This bias is 
expected to be nondifferential, thus minimising the magnitude of the overall 
estimate.  
 
Misclassification of dementia and subtypes is also possible, and indeed likely 
given the challenges of classifying dementia subtypes [13, 23]. Compared to 
people without a stroke, people with a history of stroke might be more likely to 
be classified as having VaD.  We speculate this may be an explanation why 
controlling for stroke was having an effect on the association of epilepsy with 
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incident dementia (especially VaD), while controlling for other cardio-vascular 
risk factors had less effect. The likelihood of misclassification of dementia and 
its subtypes along with the moderate effect size of hazard ratios could cast doubt 
on the observation of valproate and an increased risk of VaD but should be of 
less concern regarding the association with dementia of any cause.   
While the model approach allowed for control of several confounders, there were 
several that we were unable to account for as described earlier.  In addition, we 
were unable to control for educational level, socioeconomic status, or genetic 
risk.   
CONCLUSION 
Our study shows that PWE appear to sustain a parallel but more rapid age-related 
increase in dementia risk, compared to those without epilepsy. Whether this 
confirms the cascadic theory of loss of cognitive power in epilepsy and or reflects 
some other aspect, such as specific treatment exposure, requires further research.  
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Table 1: Number of people exposed to an anti-epileptic drug, total and of those 




Carbamazepine 9,148 3,660 
Clonazepam 3,271 590 




Primidone 1042 410 
Valproate 6,555 4,162 
Lamotrigine 2,535 1,866 
Gabapentin 34,925 3,199 
Topiramate 973 357 
Levetiracetam 2,590 1,977 
Pregabalin 16,258 1,604 




Table 2: Predicted HR of the effect of epilepsy on dementia incidence adjusting 
for a selection of individual covariates. Each row represents the adjustment for 
the named covariate alone.   
 
Dementia Alzheimers VaD 
Covariate HR (95% CI) HR (95% CI) HR (95% CI) 
None 2.5 (2.3 to 2.6) 1.6 (1.4 to 1.8) 3.1 (2.8 to 3.4) 
Smoking 2.4 (2.3 to 2.6) 1.6 (1.4 to 1.8) 3.0 (2.7 to 3.3) 
Stroke 2.0 (1.9 to 2.1) 1.5 (1.3 to 1.7) 2.0 (1.8 to 2.3) 
Diabetes 2.4 (2.3 to 2.6) 1.6 (1.4 to 1.8) 3.0 (2.7 to 3.3) 
Hypertension 2.4 (2.3 to 2.6) 1.6 (1.5 to 1.8) 3.0 (2.7 to 3.3) 
Alcohol 2.3 (2.2 to 2.5) 1.6 (1.4 to 1.8) 2.9 (2.6 to 3.2) 
Head injuries 2.3 (2.2 to 2.5) 1.5 (1.4 to 1.7) 2.8 (2.6 to 3.1) 
High 




Table 3: Adjusted hazard ratio of the effect of exposure to anti-epileptic drugs on 
dementia, Alzheimer’s disease and vascular dementia. Adjusted Hazard ratios 
compare the dementia hazard in people with epilepsy exposed to a specific drug 
with the dementia hazard in those not exposed to that specific drug (any other 
drug).  
 
Dementia Alzheimers VaD 
Drug HR (99% CI)1,2 HR (99% CI)1,2 HR (99% CI)1,2 
Carbamazepine 1.1 (0.9 to 1.3) 1.2 (0.9 to 1.8) 1.0 (0.8 to 1.4) 
Clonazepam 1.1 (0.7 to 1.5) 0.9 (0.4 to 2.0) 1.0 (0.6 to 1.9) 
Phenobarbital 0.8 (0.6 to 1.2) 0.7 (0.3 to 1.5) 0.7 (0.4 to 1.3) 
Phenytoin 1.0 (0.9 to 1.3) 1.2 (0.8 to 1.7) 1.0 (0.7 to 1.4) 
Primidone 1.1 (0.7 to 1.7) 1.5 (0.7 to 3.3) 1.5 (0.8 to 2.8) 
Valproate 1.6 (1.4 to 1.9) 1.2 (0.8 to 1.6) 1.7 (1.3 to 2.3) 
Lamotrigine 1.1 (0.9 to 1.4) 1.5 (1.0 to 2.3) 1.0 (0.7 to 1.5) 
Gabapentin 0.6 (0.5 to 0.8) 0.6 (0.4 to 0.9) 0.7 (0.5 to 1.0) 
Topiramate 1.2 (0.7 to 2.0) 0.4 (0.1 to 2.7) 1.0 (0.4 to 2.6) 
Levetiracetam 1.0 (0.8 to 1.2) 0.7 (0.4 to 1.2) 0.8 (0.6 to 1.2) 
Pregabalin 0.7 (0.5 to 0.9) 0.8 (0.5 to 1.4) 0.7 (0.4 to 1.1) 
Valproate3 1.5 (1.3 to 1.8) 1.3 (0.8 to 1.6) 1.4 (1.1 to 1.9) 
Valproate4 1.6 (1.4 to 1.9) 1.1 (0.8 to 1.6) 1.7 (1.3 to 2.3) 
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1    All estimates adjusted for sex. 
2 To compensate for multiple testing, 99%CI’s provided 
3    Adjusted for sex and stroke. 
4    Adjusted for sex and Bipolar Disorder. 
 
31 Schnier 
Figure 1: Predicted hazard of dementia, Alzheimer’s disease and Vascular 
dementia for people with and without epilepsy, free of dementia at age 60. 
Figure 2: Age at first epilepsy-related electronic health record by sex. 
Figure 3: Predicted hazard of dementia, Alzheimer’s disease and Vascular 
dementia for people free of dementia at age 60, by age at first epilepsy-related 
EHR. 
Figure 4: Predicted hazard of dementia for people free of dementia at age 60, 
by ever-exposure to different anti-epileptic drugs. 
 
